Shots:
- MediLink has entered into an additional collaboration & exclusive licensing agreement with Roche for the development & commercialization of YL201 (B7H3 ADC) across numerous solid tumor types
- Under the deal, Roche will obtain an exclusive license to develop, manufacture, & commercialize YL201 worldwide, excl. Mainland China, Hong Kong SAR, & Macau SAR
- In return, MediLink will receive an upfront & near-term milestone payments of $570M, along with additional development, regulatory, & commercial milestones, plus tiered royalties on net ex-China sales of YL201
Ref: PRnewswire | Image: MediLink & Roche | Press Release
Related News: Roche Receives the US FDA Approval of Lunsumio VELO for Subcutaneous Use in R/R Follicular Lymphoma
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
